7:35AM Vertex Pharm provides Interim Data from Phase 2 Study (VRTX) 49.45 : Co announces interim results from ZENITH, an ongoing Phase 2 study designed to assess the safety, tolerability and efficacy of multiple 12- and 24-week response-guided treatment regimens with VX-222, its lead polymerase inhibitor in development, in combination with INCIVEK tablets, pegylated-interferon and ribavirin in people with genotype 1 chronic hepatitis C who were new to treatment. This is an interim analysis from patients in the four-drug treatment arms and was conducted after these patients completed their assigned treatment. Results showed that 50% of people in the study who received VX-222 in combination with INCIVEK, pegylated-interferon and ribavirin were eligible to stop all treatment at week 12, and 93 percent of these patients had undetectable hepatitis C virus 12 weeks after treatment ended. Patients from the VX-222 treatment arm who were not eligible to stop all treatment at week 12 received an additional 12 weeks of pegylated-interferon and ribavirin alone for 24 total weeks of treatment. The hepatitis C virus was undetectable in 100% of these patients at the end of 24 weeks. In this study, VX-222, INCIVEK and ribavirin were given twice daily. Interim safety results from the four-drug treatment arms showed that mild gastrointestinal symptoms and mild fatigue were the most frequently reported adverse events. Side effects consistent with the known safety profile of INCIVEK combination treatment also were observed.
surf's up......crikey
